surmount trial tirzepatide Presented today at #ECO2026 ⤵️ The SURMOUNT-MAINTAIN found that continuing at the maximum tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity. Explore the research: https://t.co/RjLxWa5qjV ESC 2025: post-hoc SURMOUNT-5 data
Description
Individuals using tirzepatide must be aware of the guidelines for use and be prepared to manage any side effects
Extended Clinic License Upgrade (MultiLocation / MultiDomain)
9 The recommendation to stop the study came from an independent data monitoring committee and will allow further research to take place
Rated 5 out of 5 Steve C
[DOI] [PMC free article] [PubMed] [Google Scholar] 8.U.S
